Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S, Jones W, Lewis J L, Almadrones L, Hoskins W
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
J Cancer Res Clin Oncol. 1992;119(1):55-7. doi: 10.1007/BF01209489.
Eighteen previously treated patients with advanced ovarian cancer were entered into a phase 2 trial of chronic low-dose oral etoposide (50 mg/day for 20 days, repeated every 28 days) to determine the activity of this therapeutic strategy in organoplatinum-refractory disease. The treatment program was generally well tolerated, with mild neutropenia the most common side-effect encountered. One patient (6%; 95% confidence interval = 0-17%) achieved a partial response, which lasted for 11 months. Three additional patients (17%), who failed to meet the criteria of a partial response, demonstrated objective evidence of antineoplastic activity. Chronic low-dose oral etoposide administration is associated with definite, although modest, activity in platinum-refractory ovarian cancer.
18例先前接受过治疗的晚期卵巢癌患者进入了一项关于慢性低剂量口服依托泊苷（50毫克/天，共20天，每28天重复一次）的2期试验，以确定这种治疗策略对铂类耐药疾病的活性。该治疗方案总体耐受性良好，轻度中性粒细胞减少是最常见的副作用。1例患者（6%；95%置信区间=0-17%）获得部分缓解，持续11个月。另外3例患者（17%）未达到部分缓解标准，但有抗肿瘤活性的客观证据。慢性低剂量口服依托泊苷给药与铂类耐药卵巢癌的明确活性相关，尽管活性程度适中。
